卡维地洛增加大鼠二甲双胍肝肾组织分布

doi:10.5246/jcps.2017.12.098

中国药学(英文版) ›› 2017, Vol. 26 ›› Issue (12): 881-889.DOI: 10.5246/jcps.2017.12.098

卡维地洛增加大鼠二甲双胍肝肾组织分布

马彦荣¹, 武艳芳^1,2, 段颖婷^1,2, 武新安^1*

1. 兰州大学第一医院药剂科, 兰州 730000
2. 兰州大学药学院, 兰州 730000

收稿日期:2017-09-17 修回日期:2017-10-11 出版日期:2017-12-27 发布日期:2017-11-23
通讯作者: Tel./Fax: +86-931-8616392, E-mail: xinanwu6511@163.com
基金资助:
National Natural Science Foundation of China (Grant No. 81373494).

Local drug interaction of metformin with carvedilol increases drug accumulation in the liver and kidney of rats

Yanrong Ma¹, Yanfang Wu^1,2, Yingting Duan^1,2, Xinan Wu^1*

1. Department of Pharmacy, the First Hospital of Lanzhou University, Lanzhou 730000, China
2. School of Pharmacy, Lanzhou University, Lanzhou 730000, China

Received:2017-09-17 Revised:2017-10-11 Online:2017-12-27 Published:2017-11-23
Contact: Tel./Fax: +86-931-8616392, E-mail: xinanwu6511@163.com
Supported by:
National Natural Science Foundation of China (Grant No. 81373494).

摘要/Abstract

摘要：

药物转运体在药物-药物相互作用中扮演着重要的角色,其能够影响众多药物在血浆和组织的暴露水平。本研究初步研究了卡维地洛对二甲双胍药动学的影响及其相互作用机制。大鼠单次或连续7天灌胃给药后,采用HPLC测定血浆、尿液和组织中二甲双胍浓度, Western blotting评价rOCTs和rMATE1的表达水平。单次或连续7天联合给予卡维地洛后,二甲双胍血浆和尿液浓度并未发生明显的改变,但肝肾组织浓度却显著增加。与此一致,离体肾灌流结果显示,卡维地洛能够显著增加二甲双胍在肾脏蓄积,但并未影响其尿排泄。此外,卡维地洛对肝肾rOCTs和rMATE1的表达水平无显著的改变。长期联合用药后,卡维地洛也未影响血清乳酸、尿酸和肌酐水平。这些结果表明,卡维地洛能够增加二甲双胍肝肾组织分布,产生局部的药物相互作用。

关键词: 二甲双胍, 卡维地洛, 药物相互作用, rOCTs, rMATE1

Abstract:

Drug transporters determine plasma and tissue exposure of a broad variety of drugs and play a critical role in drug-drug interaction (DDI). In the present study, we aimed to investigate the effects of carvedilol on pharmacokinetics of metformin as well as the mechanism of their interaction. Results showed that plasma concentration of metformin was not significantly altered after single or 7-day co-administration of carvedilol, and the urinary excretion of metformin was also not influenced by carvedilol.However, the concentration of metformin in the liver and kidney was markedly elevated. Similarly, carvedilol did not affect the renal elimination of metformin, but increased renal concentration in isolated kidney perfusion. On the other hand, carvedilol treatment did not affect the expressions of rOCTs and rMATE1 in the liver and kidney of rats. After long-term co-administration, there were no differences in lactic acid (LCA), uric acid (URIC) and creatinine (CREA) levels between two groups. These results indicated that carvedilol increased hepatic and renal distribution of metformin, resulting in local drug interaction.

Key words: Metformin, Carvedilol, Drug interaction, rOCTs, rMATE1

中图分类号:

R969.1

Supporting:

马彦荣, 武艳芳, 段颖婷, 武新安. 卡维地洛增加大鼠二甲双胍肝肾组织分布[J]. 中国药学(英文版), 2017, 26(12): 881-889.

Yanrong Ma, Yanfang Wu, Yingting Duan, Xinan Wu. Local drug interaction of metformin with carvedilol increases drug accumulation in the liver and kidney of rats[J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(12): 881-889.

参考文献

[1] Martin-Montalvo, A.; Mercken, E.M.; Mitchell, S.J.; Palacios, H.H.; Mote, P.L.; Scheibye-Knudsen, M.; Gomes, A.P.; Ward, T.M.; Minor, R.K.; Blouin, M.J.; Schwab, M.; Pollak, M.; Zhang, Y.; Yu, Y.; Becker, K.G.; Bohr, V.A.; Ingram, D.K.; Sinclair, D.A.; Wolf, N.S.; Spindler, S.R.; Bernier, M.; de Cabo, R. Nat. Commun. 2013, 4, 2192.

[2] Gong, L.; Goswami, S.; Giacomini, K.M.; Altman, R.B.; Klein, T.E. Pharmacogenet. Genom. 2012, 22, 820-827.

[3] Bachmakov, I.; Glaeser, H.; Endress, B.; Morl, F.; Konig, J.; Fromm, M.F. Diabetes. Obes. Metab. 2009, 11, 1080-1083.

[4] Motohashi, H.; Inui, K. AAPS. J. 2013, 15, 581-588.

[5] Busch, A.E.; Karbach, U.; Miska, D.; Gorboulev, V.; Akhoundova, A.; Volk, C.; Arndt, P.; Ulzheimer, J.C.; Sonders, M.S.; Baumann, C.; Waldegger, S.; Lang, F.; Koepsell, H. Mol. Pharmacol. 1998, 54, 342-352.

[6] Sekar, K.; Sekharudu, C.; Tsai, M.D.; Sundaralingam, M. Acta Crystallogr. D. Acta. Crystallogr. 1998, 54, 342-346.

[7] Li, Y.; Yin, X.; Chen, X.; Li, X.; Li, J.; Liu, C.; Liu, M.; Zhang, Y. Virus. Res. 2012, 163, 546-551.

[8] Wang, D.S.; Jonker, J.W.; Kato, Y.; Kusuhara, H.; Schinkel, A.H.; Sugiyama, Y. J. Pharmacol. Exp. Ther. 2002, 302, 510-515.

[9] Misaka, S.; Knop, J.; Singer, K.; Hoier, E.; Keiser, M.; Muller, F.; Glaeser, H.; Konig, J.; Fromm, M.F. Mol. Pharm. 2016, 13, 512-519.

[10] Yin, J.; Duan, H.; Shirasaka, Y.; Prasad, B.; Wang, J. Drug Metab. Dispos. 2015, 43, 1872-1881.

[11] Ma, Y.R.; Huang, J.; Shao, Y.Y.; Ma, K.; Zhang, G.Q.; Zhou, Y.; Zhi, R.; Qin, H.Y.; Wu, X.A. Eur. J. Pharm. Sci. 2015, 68, 18-26.

[12] Xu, Q.; Wang, C.; Meng, Q.; Liu, Q.; Sun, P.; Sun, H.; Guo, X.; Liu, K. Eur. J. Pharm. Sci. 2014, 52, 41-47.

[13] Sprowl, J.A.; Ong, S.S.; Gibson, A.A.; Hu, S.; Du, G.; Lin, W.; Li, L.; Bharill, S.; Ness, R.A.; Stecula, A.; Offer, S.M.; Diasio, R.B.; Nies, A.T.; Schwab, M.; Cavaletti, G.; Schlatter, E.; Ciarimboli, G.; Schellens, J.H.; Isacoff, E.Y.; Sali, A.; Chen, T.; Baker, S.D.; Sparreboom, A.; Pabla, N. Nat. Commun. 2016, 7, 10880.

[14] Jonas, M.; Reicher-Reiss, H.; Boyko, V.; Shotan, A.; Mandelzweig, L.; Goldbourt, U.; Behar, S. Am. J. Cardiol. 1996, 77, 1273-1277.

[15] Dahlof, B.; Sever, P.S.; Poulter, N.R.; Wedel, H.; Beevers, D.G.; Caulfield, M.; Collins, R.; Kjeldsen, S.E.; Kristinsson, A.; McInnes, G.T.; Mehlsen, J.; Nieminen, M.; O’Brien, E.; Ostergren, J. Lancet. 2005, 366, 895-906.

[16] Jacob, S.; Rett, K.; Wicklmayr, M.; Agrawal, B.; Augustin, H.J.; Dietze, G.J. J. Hypertens. 1996, 14, 489-494.

[17] Fonseca, V.; Bakris, G.L.; Bell, D.S.; McGill, J.B.; Raskin, P.; Messerli, F.H.; Phillips, R.A.; Katholi, R.E.; Wright Jr, J.T.; Waterhouse, B.; Lukas, M.A.; Anderson, K.M. Diabet. Med. 2007, 24, 759-763.

[18] Dunn, C.J.; Peters, D.H. Drugs. 1995, 49, 721-749.

[19] Foretz, M.; Guigas, B.; Bertrand, L.; Pollak, M.; Viollet, B. Cell Metab. 2014, 20, 953-966.

[20] Ma, Y.R.; Shi, A.X.; Qin, H.Y.; Zhang, T.; Wu, Y.F.; Zhang, G.Q.; Wu, X.A. Biopharm. Drug Dispos. 2016, 37, 511-521.

[21] Bachmakov, I.; Glaeser, H.; Endress, B.; Mörl, F.; König, J.; Fromm, M.F. Diabetes Obes. Metab. 2009, 11, 1080-1083.

[22] Hokama, N.; Hobara, N.; Kameya, H.; Ohshiro, S.; Sakanashi, M. J. Chromatogr. B. 1999, 732, 233-238.

[23] Lee, W.; Woo, E.R.; Choi, J.S. Pharm. Biol. 2012, 50, 516-522.

[24] Avkiran, M.; Haworth, R.S. Cardiovasc. Res. 2003, 57, 942-952.
[25] De Giusti, V.C.; Nolly, M.B.; Yeves, A.M.; Caldiz, C.I.; Villa-Abrille, M.C.; Chiappe de Cingolani, G.E.; Ennis, I.L.; Cingolani, H.E.; Aiello, E.A. Hypertension. 2011, 58, 912-919.

卡维地洛增加大鼠二甲双胍肝肾组织分布

Local drug interaction of metformin with carvedilol increases drug accumulation in the liver and kidney of rats

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 13

编辑推荐

Metrics

本文评价

[1]	李莹, 文周, 刘永玲, 赵治兵, 王磊, 程泽能. 高效液相色谱法测定大鼠血浆中阿昔洛韦浓度及其与吉非替尼药物相互作用的研究[J]. 中国药学(英文版), 2021, 30(6): 495-504.
[2]	李岩, 孟雨晴, 逯颖媛, 常坤, 高鹏, 姜勇, 屠鹏飞, 郭晓宇. 三七-红花有效组分复方对人肝微粒体中UGT1A1、1A4和2B7活性抑制作用的研究[J]. 中国药学(英文版), 2019, 28(4): 229-237.
[3]	严妍, 李玲, 李蕊, 于文君, 韩毅, 马玉奎, 李妍. 二甲双胍原研制剂格华止?与一种仿制制剂在大鼠模型中药代动力学和药效学比较[J]. 中国药学(英文版), 2019, 28(2): 134-142.
[4]	张杜娟, 陈克广, 张蕊, 袁桂艳, 王本杰, 郭瑞臣. 大鼠体内瑞舒伐他汀和瑞格列奈药动学和肝脏分布相互作用研究[J]. 中国药学(英文版), 2018, 27(1): 22-30.
[5]	刘园园, 梁舒瑶, 陈恳, 张帆, 刘芳. 伏立康唑对联合使用药物的药代动力学和安全性的影响: 系统评价[J]. 中国药学(英文版), 2016, 25(11): 785-798.
[6]	张亚同, 郑子恢, 梁欣, 胡欣, 李可欣. 胺碘酮和CYP2C9、VKORC1基因型对华法林抗凝效果的影响分析[J]. 中国药学(英文版), 2014, 23(3): 190-193.
[7]	杨思敏, 姬利延, 阙琳玲, 王夔, 余四旺. 二甲双胍激活Nrf2信号并诱导抗氧化基因的表达[J]. 中国药学(英文版), 2014, 23(12): 837-843.
[8]	陈烨, 李汉青, 许娇娇, 酒向飞, 邓晨辉, 李新刚, 李良, 徐小晴, 周田彦^, 卢炜^. 高效液相离子对色谱法测定糖尿病大鼠血浆中二甲双胍浓度及其药代动力学研究[J]. , 2012, 21(3): 211-218.
[9]	魏兰兰, 孙佩男, 田蕾, 唐歆, 姚婷婷, 潘卫三^*. 卡维地洛固体自微乳化药物传递系统的应用[J]. , 2006, 15(4): 223-227.
[10]	刘宏飞, 苏显英, 李想, 赵欣, 臧蕾, 潘卫三^*. 盐酸二甲双胍缓释微囊的制备[J]. , 2006, 15(3): 155-161.
[11]	欧阳德方, 孟晋, 孔翠凤, 聂淑芳, 潘卫三^*. 复方二甲双胍/格列吡嗪单室渗透泵片的释药机理[J]. , 2006, 15(2): 92-96.
[12]	欧阳德方, 聂淑芳, 孟晋, 杨星钢, 宋志全, 潘卫三^*. 复方二甲双胍/格列吡嗪双层缓释片: 设计与体外释放[J]. , 2005, 14(3): 169-172.
[13]	弋苹, 全钰珠. 西米替丁降低吡喹酮在大鼠体内的消除[J]. , 1993, 2(2): 127-132.